Key result
Aliskiren and valsartan significantly attenuated albuminuria, urinary nephrin excretion, and glomerulosclerosis in mice with diabetic nephropathy, with synergistic effects in dual therapy.
Why the study?
Does aliskiren or valsartan improve markers of diabetic nephropathy in a mouse model?
Population
DBA/2J mice with diabetic nephropathy induced by streptozotocin (40 mg/kg/day x 5 days) and high fat diet
Comparison
Aliskiren or valsartan or dual treatment for 6… vs Untreated diabetic mice
Design
Preclinical
Follow-up
6 weeks
Authors
Loading...
Supports dual blockade in mouse diabetic nephropathy models; leaves open clinical translation to human disease.
Does aliskiren or valsartan improve markers of diabetic nephropathy in a mouse model?
Aliskiren and valsartan demonstrate protective effects against diabetic kidney disease in a mouse model through multiple mechanisms including reduction of podocyte injury, inflammation, and ER stress.
Wang et al. (2014) studied Diabetic nephropathy. Aliskiren vs. Valsartan (8 mg/kg/day) or dual treatment was evaluated on Albuminuria, urinary nephrin excretion and glomerulosclerosis. Aliskiren and valsartan significantly attenuated albuminuria, urinary nephrin excretion, and glomerulosclerosis in mice with diabetic nephropathy, with synergistic effects in dual therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: